Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PaxVax Corporation
The company’s next-generation kinase inhibitors are designed to target unaddressed mutations and overcome treatment resistance. Lead programs focus on BRAF Class II and III mutations and FGFR2/3.
US FDA’s Medical Countermeasures Initiative authorities like emergency use authorization have not yet had much of an impact on drugs and biologics, but agency is committed to supporting a swift response to the new strain of coronavirus.
As the mosquito-borne chikungunya virus spreads into temperate regions worldwide, US FDA convenes advisory committee for an open discussion on development of vaccines.
Following its purchase of PaxVax earlier this month, Emergent is taking on Narcan nasal spray for opioid overdose as part of its acquisition of Adapt. Also-busy Evotec teams up with Centogene in rare genetic disease and Novo in diabetes/obesity.